This week’s episode will be focusing on the 2026 ASCO Plenary that received a standing ovation, the RASolute 302 trial. The RASolute 302 trial is a landmark phase 3 study demonstrating that daraxonrasib doubled overall survival compared to chemotherapy in previously treated (2L) metastatic pancreatic ductal adenocarcinoma (mPDAC).
Oct 2025
Esophageal & Gastric Cancer
Send us Fan MailNinja Nerds!In this episode of the Ninja Nerd Podcast, Zach and Rob discuss two high-yield, board-relevant cases highlighting the diagnosis, staging, and treatment of esophageal adenocarcinoma and intestinal-type gastric adenocarcinoma.We begin with a 56-year-old ... Show More
28m 56s
Nov 2025
Pancreatic and Hepatobiliary Cancer
Send us Fan MailNinja Nerds!In this episode of the Ninja Nerd Podcast, Zach and Rob explore pancreatic and hepatobiliary cancers through four patient cases packed with clinical pearls.We begin with a 63-year-old man presenting with painless jaundice, pruritus, and weight loss. Za ... Show More
37 m